Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:KALV NASDAQ:KURA NASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.71+1.1%$3.33$2.70▼$4.72$703.53M0.86821,910 shs766,346 shsKALVKalVista Pharmaceuticals$13.46-0.4%$13.50$7.30▼$16.32$680.09M0.05656,497 shs436,472 shsKURAKura Oncology$7.90-2.1%$6.43$5.41▼$21.57$700.45M0.411.94 million shs1.68 million shsMOLNMolecular Partners$3.83+6.3%$3.70$3.36▼$7.60$145.36M1.14,219 shs4,139 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+1.09%+3.34%+12.42%+10.42%-3.64%KALVKalVista Pharmaceuticals-0.37%+0.37%-2.75%+14.46%+4.42%KURAKura Oncology-2.11%+3.27%+25.40%+39.08%-60.77%MOLNMolecular Partners+3.24%+1.73%+1.49%-2.02%-39.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.6528 of 5 stars3.51.00.00.03.62.50.6KALVKalVista Pharmaceuticals3.6504 of 5 stars3.61.00.04.42.00.80.6KURAKura Oncology3.9398 of 5 stars3.43.00.04.72.50.00.6MOLNMolecular Partners1.72 of 5 stars3.82.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5048.25% UpsideKALVKalVista Pharmaceuticals 3.11Buy$26.2995.29% UpsideKURAKura Oncology 2.86Moderate Buy$24.10205.06% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00213.73% UpsideCurrent Analyst Ratings BreakdownLatest MOLN, ABUS, KURA, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/11/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$28.00 ➝ $24.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M115.27N/AN/A$0.43 per share8.63KALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AKURAKura Oncology$53.88M12.73N/AN/A$3.52 per share2.24MOLNMolecular Partners$681K226.78N/AN/A$3.20 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.29N/AN/AN/A-352.24%-59.28%-44.11%11/5/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.69N/AN/AN/AN/A-134.07%-82.65%9/4/2025 (Estimated)KURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)MOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)Latest MOLN, ABUS, KURA, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91N/AN/AN/A$1.97 millionN/A8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million8/6/2025Q2 2025ABUSArbutus Biopharma-$0.02$0.01+$0.03$0.01$2.21 million$10.74 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A20.5320.53KALVKalVista PharmaceuticalsN/A5.355.35KURAKura Oncology0.026.166.16MOLNMolecular PartnersN/A9.3515.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%KALVKalVista PharmaceuticalsN/AKURAKura OncologyN/AMOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%KALVKalVista Pharmaceuticals4.30%KURAKura Oncology6.40%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.70 million152.78 millionOptionableKALVKalVista Pharmaceuticals10050.34 million48.18 millionOptionableKURAKura Oncology13086.80 million81.24 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableMOLN, ABUS, KURA, and KALV HeadlinesRecent News About These CompaniesLeerink Partnrs Issues Optimistic Estimate for MOLN EarningsAugust 30 at 6:31 AM | marketbeat.comQ3 EPS Forecast for Molecular Partners Lifted by AnalystAugust 30 at 2:45 AM | americanbankingnews.comMolecular Partners (NASDAQ:MOLN) Issues Quarterly Earnings ResultsAugust 27 at 4:38 PM | marketbeat.comMolecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025August 25, 2025 | globenewswire.comMolecular Partners (MOLN) Projected to Post Quarterly Earnings on MondayAugust 23, 2025 | americanbankingnews.comMolecular Partners appoints Martin Steegmaier as chief scientific officerAugust 21, 2025 | msn.comMolecular Partners (MOLN) Expected to Announce Earnings on MondayAugust 19, 2025 | marketbeat.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 0.7% - Should You Sell?August 16, 2025 | marketbeat.comMolecular Partners AG ADR MOLN (U.S.: Nasdaq) - The Wall Street JournalAugust 5, 2025 | wsj.comMolecular Partners AG News (MOLN) - Investing.comJuly 2, 2025 | investing.comMolecular Partners AG (MOLN) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comMolecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - MorningstarJune 24, 2025 | morningstar.comMMolecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025June 22, 2025 | globenewswire.comMolecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA CongressJune 12, 2025 | nasdaq.comMolecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025June 11, 2025 | uk.finance.yahoo.comMolecular Partners to cut jobs, cash reach now anticipated to extend into 2028June 10, 2025 | msn.comMolecular Partners Announces Planned Operational Efficiencies and Extension of Cash RunwayJune 10, 2025 | globenewswire.comMolecular Partners to Present at Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comMolecular Partners Reports Financial Results and Highlights from Q1 2025May 15, 2025 | finance.yahoo.comMolecular Partners presents new data on Radio-DARPin, Switch-DARPin programsApril 26, 2025 | markets.businessinsider.comMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025April 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMOLN, ABUS, KURA, and KALV Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.71 +0.04 (+1.09%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.72 +0.00 (+0.13%) As of 08/29/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.KalVista Pharmaceuticals NASDAQ:KALV$13.46 -0.05 (-0.37%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.75 +0.29 (+2.15%) As of 08/29/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Kura Oncology NASDAQ:KURA$7.90 -0.17 (-2.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.03 +0.13 (+1.59%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Molecular Partners NASDAQ:MOLN$3.82 +0.23 (+6.25%) Closing price 08/29/2025 02:17 PM EasternExtended Trading$3.78 -0.05 (-1.31%) As of 08/29/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
